Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. reported the grant of 44,409 restricted stock units (RSUs) to 15 newly hired non-executive officers. These awards, approved by the compensation committee, were made under the Ultragenyx Employment Inducement Plan as an incentive for new employees. The RSUs will vest over four years, with 25% of the shares vesting on each anniversary of the June 16, 2026 grant date, contingent on continuous employment.

Ultragenyx Pharmaceutical Inc. announced that its President and CEO, Emil Kakkis, M.D., Ph.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference. The event is scheduled for Tuesday, June 9, 2026, at 4:00 PM ET. A live and archived webcast of the fireside chat will be accessible on the company's investor relations website.

Ultragenyx Pharmaceutical Inc. reported the grant of 17,567 restricted stock units (RSUs) of its common stock to 11 newly hired non-executive officers. These awards, approved by the compensation committee, were granted on May 16, 2026, under the Ultragenyx Employment Inducement Plan. The RSUs vest over four years, with 25% vesting on each anniversary of the grant date, contingent on continuous employment.

Ultragenyx Pharmaceutical Inc. held its Annual Meeting of Stockholders on May 14, 2026. Stockholders elected three Class I directors to serve until the 2029 Annual Meeting and approved the Third Amended and Restated 2023 Incentive Plan. Additionally, the selection of Ernst & Young LLP as the independent registered accounting firm for 2026 was ratified, and executive compensation was approved on an advisory basis.

Ultragenyx Pharmaceutical Inc. announced that its Chief Financial Officer, Howard Horn, and Chief of Staff, Joshua Higa, will participate in a fireside chat at Bank of America's 2026 Healthcare Conference. The event is scheduled for Tuesday, May 12, 2026, at 2:20 PM PT. A live and archived webcast will be accessible on the company's investor relations website.

Ultragenyx Pharmaceutical Inc. reported a net loss of $(185) million for the first quarter of 2026, an increase from $(151) million in the prior year, on total revenues of $136 million, down from $139 million. The company experienced increased operating expenses, particularly in research and development, and a significant decrease in cash and cash equivalents. Ultragenyx is pursuing a restructuring plan announced in February 2026 and aims for profitability in 2027.

Ultragenyx Pharmaceutical Inc. reported Q1 2026 total revenue of $136 million, a slight decrease from $139 million in Q1 2025, with a net loss of $185 million. The company reaffirmed its full year 2026 total revenue guidance of $730 million to $760 million and remains on track for profitability in 2027. Key clinical milestones include FDA acceptance of BLAs for DTX401 and UX111 with PDUFA dates in August and September 2026, respectively, and Phase 3 data for GTX-102 expected in the second half of 2026.

Ultragenyx Pharmaceutical Inc. granted 36,447 restricted stock units (RSUs) to 12 newly hired non-executive officers on April 16, 2026. These awards were approved by the compensation committee under the Ultragenyx Employment Inducement Plan, serving as an inducement for the new employees to join the company. The RSUs will vest over four years, with 25% vesting on each anniversary of the grant date, contingent on continuous employment.